To recover your password please fill in your email address
Please fill in below form to create an account with us
A phase III study to evaluate the efficacy and safety of pazopanib monotherapy versus placebo in women whose disease has not progressed after first-line chemotherapy for epithelial ovarian, fallopian tube or primary peritoneal cancer
|
Trial Summary: |
This study is for women who have FIGO stages II-IV ovarian, fallopian tube or primary peritoneal cancer that has not progressed after first-line chemotherapy. Approximately 900 women are being randomly allocated to pazopanib, 800 mg daily, or placebo. Treatment continues for 52 weeks unless the participant dies or discontinues treatment. The primary objective of the study is to determine whether pazopanib prolongs progression-free survival. Throughout the study, all participants have safety and efficacy assessments, which include physical examinations, blood tests, CT or MRI scans and questionnaires. |
|
Supported By: |
GlaxoSmithKline; Australia New Zealand Gynaecological Oncology Group (ANZGOG); Arbeitsgemeinschaft Gynackologisehe Onkologie (AGO) Ovarian Cancer Study Group |
|
Eligibility: |
Women with epithelial ovarian, fallopian tube, or primary peritoneal cancer |
|
Registration ID: |
ACTRN12609000591257 |
|
Participation: |
International |
|
Australian Lead Group: |
ANZGOG |
|
Status: |
Closed |
|
Activation Date: |
14/08/2009 |
|
Chairs: |
Michael Friedlander (Australia) |
|
Contact: |